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Summary
The dipeptide boronic acid bortezomib, also termed
VELCADE, is a proteasome inhibitor now in use for
the treatment of multiple myeloma, and its use for the
treatment of other malignancies is being explored.
We determined the crystal structure of the yeast 20S
proteasome in complex with bortezomib to establish
the specificity and binding mode of bortezomib to the
proteasome’s different catalytically active sites. This
structure should enable the rational design of new
boronic acid derivatives with improved affinities and
specificities for individual active subunits.
Introduction
The ubiquitin-proteasome pathway plays a central role in
proteolysis (Groll et al., 2005; Hershko and Ciechanover,
1998). The proteolytic component of this system, the 26S
proteasome, consists of two 19S regulatory particles
(RPs), involved in substrate recognition and unfolding,
and a core particle (CP) termed 20S proteasome. The
CP possesses a unique barrel-shaped structure, which
contains 28 protein subunits, arranged in 4 stacked
rings, each subunit occupying unique locations within
the molecule (Groll et al., 1997; Lo¨we et al., 1995). The
outer a rings of the a7b7b7a7 complex interact with the
RPs, whereas the two inner b rings harbor the proteolyt-
ically active sites. In eukaryotic proteasomes, three
b-type subunits, b1, b2 and b5, contain proteolytically
active centers (Groll et al., 1997). Catalytic activities of
these active b-type subunits are associated with their
N-terminal threonine residue,which actsasanucleophile
in hydrolysis, thus classifying proteasomes as members
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erlands.of the family of Ntn (N-terminal nucleophilic) hydrolases
(Brannigan et al., 1995; Lo¨we et al., 1995). Proteasomes
can cleave after most amino acids: proteolytic activity
measured against fluorogenic substrates illustrates
three distinct cleavage preferences, termed chymotryp-
tic, tryptic, and caspase-like activities (Orlowski et al.,
1993), which can roughly be assigned to the subunits
b5, b2, and b1, respectively (Figure 1A) (Groll et al., 1999).
Since proteasomes are responsible for the cytoplas-
mic turnover of the vast majority of proteins, and are
hence central to many cellular processes, the manipula-
tion of proteasomal activity is a key goal in controlling
the stability of regulatory proteins (Groll and Huber,
2004; Kisselev and Goldberg, 2001). While proteasome
inhibitors have been used extensively as investigative
tools, the observation that they cause apoptosis in cer-
tain tumor-derived cell lines has led to their application
as potential cancer therapeutics (Adams et al., 1998).
The proteasome inhibitor bortezomib has been ap-
proved for the treatment of multiple myeloma patients
(Ludwig et al., 2005; Richardson et al., 2005; Teicher
et al., 1999).
Although crystal structures of the proteasome CP
complexed with peptide aldehyde-based inhibitors are
known (Groll and Huber, 2004; Kisselev and Goldberg,
2001), the X-ray structure of bortezomib with the 20S
proteasome has not been reported. Here, we establish
the crystal structure of the yeast 20S proteasome in
complex with bortezomib at 2.8 A˚ resolution. The struc-
tural data for the bortezomib-proteasome complex pre-
sented here explain the different in vivo binding affinities
of bortezomib for the individual subunits at atomic reso-
lution. Subunit specificities can roughly be attributed to
interactions of the leucine, pyrazine, and boronate moi-
eties. Our data provide opportunities for future drug
improvement.
Results
Under physiological conditions, the dipeptide boronic
acid bortezomib preferentially targets the proteasomal
b5 active site and, to a lesser extent, the b1 site, while
the b2 site is left relatively untouched (b5>b1>>b2)
(Berkers et al., 2005). Analysis of the structure of the
yeast 20S proteasome complexed with bortezomib
shows all active sites occupied by the inhibitor, attribut-
able to the high concentrations of the ligand (10 mM)
used in the course of crystal soaking. The specificity
pockets of individual active subunits do not only differ
in charge pattern, but also in their overall architecture.
Nevertheless, the binding mode of bortezomib to all
three subunits is identical.
Binding to the Bortezomib Peptide Backbone
In its bound conformation, bortezomib adopts an anti-
parallel b sheet conformation (Figure 1B), filling the gap
between strands S2 and S4. These b sheets are stabi-
lized by direct hydrogen bonds between the conserved
residues (Gly47N, Thr21N, Thr21O, and Ala49O) of the
b-type subunits and main chain atoms of the drug
Structure
452Figure 1. Structural Representation of Bortezomib Bound to Distinct Active Sites
(A) Surface representation of the yeast 20S proteasome (blue) crystallized in the presence of bortezomib, clipped along the cylindrical pseudo-7-
fold symmetry axis (white). The various proteolytic surfaces are marked by a specific color coding: red = subunit b1; blue = subunit b2; and green =
subunit b5. Cleavage preferences, termed chymotryptic-like, caspase-like, and tryptic-like activity, are zoomed and illustrated in surface repre-
sentations; the nucleophilic threonine and bortezomib are presented as a ball-and-stick model. Basic residues are colored blue, acidic residues
are red, and hydrophobic residues are white.
(B) Stereorepresentation of the chymotryptic-like active site of the yeast 20S proteasome (white and gray) and bortezomib (green). Covalent link-
age of the inhibitor with the active site Thr1 of subunit b5 is drawn in pink. The electron density map (blue) is contoured from 1.2s, with 2FO-FC
coefficients after 2-fold averaging. Apart from the bound inhibitor, structural changes were noted only in the specificity pockets. Temperature
factor refinement indicates full occupancy of bortezomib bound to the chymotryptic-like active site. Bortezomib has been omitted for phasing.(Figure 2). Thr21O and Ala49N, both of which are con-
served in all proteolytically active centers, are essential
forb sheet formation: respective carbonyl oxygen and ni-
trogen atoms tightly interact with bortezomib’s pyrazine-
2-carboxyl-phenylalanyl peptide backbone. The binding
mode and conformation is uniform in all proteolytically
active sites. Nonetheless, bortezomib exhibits different
binding affinities to distinct active sites, due to interac-
tions of the individual side chains of the inhibitor with
protein specificity pockets.Mechanism of Action: The Boronic Acid Moiety
The boronic acid moiety of the drug ensures increased
specificity for the proteasome, as opposed to earlier
generations of synthetic inhibitors, such as peptide alde-
hydes, which show cross-reactivity toward cysteine pro-
teases and low metabolic stability (Vinitsky et al., 1992).
The boronic acid core ensures high affinity for hard
oxygen nucleophiles in contrast to soft cysteine nucleo-
philes, according to the Lewis hard-soft acid-base prin-
ciple. As expected, the boron atom covalently interacts
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453with the nucleophilic oxygen lone pair of Thr1Og (Fig-
ure 1B), while Gly47N, stabilizing the oxyanion hole, is
hydrogen-bridged to one of the acidic boronate hydroxyl
groups. The tetrahedral boronate adduct is further stabi-
lized by a second acidic boronate hydroxyl moiety, which
hydrogen-bridges the N-terminal threonine amine atom,
functioning as a catalytic proton acceptor (Figure 2).
Boronic acid derivatives, and particularly peptide
boronates, are well-known inhibitors of serine proteases
(Walker and Lynas, 2001). Crystal structure elucidation
and NMR characterization of trypsin:boronic acid com-
plexes have revealed a covalent binding of the nucleophilic
Ser195Og to the boronic acid moiety, resulting in a serine-
boronate tetrahedral transition state complex (London and
Gabel, 2001; London and Gabel, 2002; Transue et al., 2004;
Weber et al., 1995). Compared to serine proteases, the
proteasomal active site, Thr1N, additionally forms a tight
hydrogen bridge to one of the boronate hydroxyl groups,
further stabilizing the protein-ligand complex, explaining
the high affinity of boronic ligands to Ntn-hydrolases.
Binding to S1 Specificity Pockets: the Leucine
Side Chain
Selectivity of inhibitors for proteasomal active sites can
be controlled by the P1-pocket, as has been shown for
Figure 2. Critical Interactions of Bortezomib with Active Site Resi-
dues Responsible for Chymotryptic and Caspase-like Activities
Schematic overview of bortezomib bound to (A) the chymotryptic-like
active site and (B) the caspase-like active site. Hydrogen bonds with
correlated distances in A˚ are shown as brown dashed lines, whereas
characteristic oxygen and nitrogen atoms are presented in red and
blue capitals. The amino acid, which is responsible for the character
and binding mode to the P3-pyrazine-2-carboxyl side chain of the in-
hibitor is located at the adjacent b-type subunit and shown in gray.
The defined water molecule forming tight hydrogen bonds to the pro-
tein is depicted in magenta, and the inhibitor is shown in green.lactacystin (Fenteany et al., 1995) and salinosporamides
(Macherla et al., 2005), and by the P3-pocket, exempli-
fied by vinylsulfone-inhibitors (Groll et al., 2002; Nazif
and Bogyo, 2001). In vivo experiments indicated that
bortezomib binds covalently with the highest affinity to
the b5 subunit (Berkers et al., 2005). Our crystallographic
analysis shows that bortezomib binds by inducing a fit to
Met45 of subunit b5, which is involved in key enzyme-
substrate interactions—in particular, those required for
hydrolysis of hydrophobic peptide bonds. Compared
to the crystal structure of the native unliganded protea-
some, the structural data of the proteasome:bortezomib
complex show that the P1-leucine side chain of the in-
hibitor shifts the side chain of Met45 from its original po-
sition by 2.7 A˚ toward Ile35. This structural rearrange-
ment enlarges the S1-specificity pocket, engaging an
induced fit, similar to what has been observed for calpain
inhibitor I (Groll et al., 1997) and epoxomycin (Groll et al.,
2000). Although the flexibility of side chains makes it dif-
ficult to predict optimal substitution at this site, we note
that, upon ligand binding, the concerted movements
allow additional hydrophobic interactions of the P1-
leucine side chain of the inhibitor with residues of the
S1-pocket, further stabilizing the ligand bound state.
The S1 specificity pocket of subunit b1, positively
charged by Arg45, is neutralized by a counter ion, adapt-
ing to the leucyl boronic acid side chain without confor-
mational rearrangements, as observed in the yeast pro-
teasome:calpain inhibitor I complex (Groll et al., 1997).
Subunit b1 can cleave peptide bonds after acidic and
branched-chain amino acids (Groll et al., 1999; Nuss-
baum et al., 1998). Interactions, in particular between
residues Thr20, Thr31, and Ala49 of subunit b1 and the
P1 leucine side chain of bortezomib, stabilize the ligand
in its bound conformation.
Bortezomib does not block the b2 active site in vivo,
even in the high micromolar range. However, our struc-
tural data exhibit clear electron density of the compound
covalently bound to subunit b2. The tryptic-like active
site displays a large unstructured S1-specificity pocket
(Groll et al., 1997), allowing for motion and flexibility of
the P1-leucine side chain of the bound ligand. Although
bortezomib adopts a b-conformation in the tryptic-like
active site, similar to that observed for subunits b1 and
b5 (Figure 1A), its P1-leucine side chain does not form
hydrophobic interactions with residues of the S1 speci-
ficity pocket. The probability of covalent binding of bor-
tezomib to the various active site threonine residues
correlates well with the affinities of the ligand for the in-
dividual binding clefts. Low binding affinity of the bo-
ronic P1-leucine side chain to the S1 pocket may lead
to a reduced occupancy of bortezomib in the tryptic-
like active site, thus increasing its IC50 value.
Binding to S2 Pockets by the Phenylalanine Residue
The phenylalanine moiety of bortezomib is not in contact
with the protein, and points into empty space. Thus, the
S2 pockets of all active sites are able to accept space-
demanding side chain residues because of their unique
topology. However, our structural data show that the
conformation of the P2-phenylalanine side chain of bor-
tezomib is flipped in the tryptic-like active site relative to
its conformation in the chymotryptic and caspase-like
active sites (Figure 1A). This result is surprising, since
Structure
454Figure 3. Comparison of Yeast and Mamma-
lian Proteasomes
(A) Stereoview of the superposition of the b5
and b6 subunits of native bovine and yeast
proteasome. The yeast b5 and b6 subunits
are colored green and yellow, respectively,
whereas subunits of the bovine liver protea-
some are colored gray. Residues, which in
particular regulate the character of the S1
and S3 pocket (Met45 and Asp114) are col-
ored black, as well as the active site threonine
residues.
(B) Individual catalytic activities of the yeast
20S proteasome against small fluorogenic
peptide substrates upon treatment with bor-
tezomib. The tryptic-like activity shows in-
creased activity at high concentrations of
bortezomib, an unexplained phenomenon
observed previously. Error bars represent 6
1 SEM.both conformations of the P2-phenylalanine side chain
of bortezomib would fit in the three distinct specificity
pockets of the various proteolytically active sites with-
out making contact with protein residues. Thus, the P2
site of bortezomib possibly contributes to overall phar-
macodynamic properties, but surely not to kinetics of in-
hibition. Presumably, specific gain may be obtained by
the introduction of large hydrophobic moieties at the
P2-site (Braun et al., 2005; Elofsson et al., 1999, Harris
et al., 2001; Kisselev et al., 2003; Nazif and Bogyo, 2001).
Binding Probabilities of Bortezomib
by the Pyrazine-2-carboxyl Group
Specific interactions are formed between the pyrazine-
2-carboxyl side chain of bortezomib and residues of
the subunit-specific S3 pockets. In the case of the chy-
motryptic-like active site, the P3 pyrazine ring is hydro-
gen-bridged to the hydroxyl group of Asp114 of the adja-
cent b6 subunit. Only one of the nitrogen atoms of the
pyrazine residue is stabilized, but the observed interac-
tion is strong, as evidenced by the short bond length of
2.9 A˚. The experimental electron density reveals a well-
defined water molecule in proximity to Asp114Og, which
coordinates a tight hydrogen bonding network, interact-
ing with b6Asp114Og, b5Ala49N, and b5Ala50N of the
protein and with the carbonyl oxygen of bortezomib
(Figure 2A). In the case of caspase-like activity, the pyra-
zine-2-carboxyl side chain is only hydrogen bridged to
Thr22Og of subunit b1 (2.9 A˚). Position 114 of the neigh-
boring subunit b2 displays a histidine residue that does
not interact with the pyrazine ring. Therefore, only the
carbonyl oxygen of b1Ala40 stabilizes the peptide back-bone of bortezomib by formation of the b conformation,
whereas a defined water molecule, present in the chymo-
tryptic-like active site, is absent in the caspase-like ac-
tive site (Figure 2B). Important interactions of the pyra-
zine ring of b2 bound bortezomib are lacking in the
tryptic-like active site. Although an aspartic residue is
present at position 114 of the adjacent subunit b3, with
similar orientations as described for the chymotryptic-
like active site, the S3 binding pockets of these two pro-
teolytically active sites differ significantly, thus providing
further explanation for the subunit selectivity of bortezo-
mib. Upon closer inspection of the pyrazine moiety, it be-
comes evident that the P3 site is also critical for the high
affinity of bortezomib to the chymotryptic-like active site.
Thus, alterations to the P1 and/or P3 sites may signifi-
cantly improve binding properties of the drug to the re-
spective proteolytically active sites (Elofsson et al.,
1999; Harris et al., 2001; Kisselev et al., 2003; Nazif and
Bogyo, 2001).
Discussion
Here we report the crystal structure of the yeast 20S pro-
teasome in complex with bortezomib. The clinical use of
this agent makes it imperative that its binding mode to
mammalian proteasomes be established, not only to
fully understand its mechanism of inhibition, but also
to provide a platform for rational improvements in spec-
ificity and strength of inhibition. The structural superpo-
sition of bovine liver (Unno et al., 2002) and yeast (Groll
et al., 1997) proteasomes shows the expected high
degree of structural similarity, despite crystallization in
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455different space groups, as illustrated in Figure 3, by
subunits b5 and b6 of the bovine and yeast CP. The abil-
ity of bortezomib to inhibit individual subunits of the
yeast 20S proteasome is consistent with kinetic data ob-
tained for mammalian proteasomes (Berkers et al., 2005;
Lightcap et al., 2000). This is shown by independent
measurements of catalytic activities of the yeast 20S
proteasome upon treatment with bortezomib as ob-
served using fluorogenic substrates in the absence of
sodium dodecylsulfate or activators (Figure 3B). So far,
biochemical and crystallographic characterization of
active site mutants has been performed only in yeast
(Chen and Hochstrasser, 1996; Heinemeyer et al., 1997;
Jager et al., 1999). Mutagenic inactivation of proteaso-
mal active site residues has revealed some striking phe-
notypes. In particular, the Thr1:Ala mutation of the active
site subunit b5 is lethal, and the Lys33:Ala mutation
causes severe growth defects, whereas the b1Thr1:Ala
and b2Thr1:Ala active site mutations are less toxic. It is
therefore important to understand the physiological
contributions of single proteasomal subunits in the
mammalian system, which can be addressed by spe-
cific, subunit-selective and cell-permeable proteasome
inhibitors. The crystal structure of bortezomib bound
to the yeast 20S proteasome illustrates concerted
movements that affect binding affinities of the inhibitor
to the proteolytic active sites.
Since bortezomib is now used for the treatment of the
universally fatal hematologic malignancy multiple mye-
loma (Richardson et al., 2005), with clinical trials for
other malignancies ongoing, it is imperative to establish
its mode of action at the molecular level. The structural
data for the bortezomib-proteasome complex pre-
sented here explain the different in vivo binding affinities
of bortezomib for the individual subunits at atomic reso-
lution. Our data immediately suggest possibilities for the
design of bortezomib derivatives with superior inhibition
characteristics, and for the design of inhibitors that will
specifically bind to single proteolytically active sites.
Thus, the crystal structure of this 20S-bortezomib com-
plex may serve as a new lead for rational design of selec-
tive boronic acid-based proteasome inhibitors.
Experimental Procedures
Cocrystallization
Crystals of 20S proteasome from Saccharomyces cerevisiae were
grown in hanging drops at 24ºC, as described previously (Groll
and Huber, 2005), and incubated for 60 min with bortezomib (10
mM in DMSO), which was synthesized essentially as described pre-
viously (Adams et al., 1998). The protein concentration used for crys-
tallization was 40 mg/ml in Tris-HCl (10 mM, pH 7.5) and EDTA (1
mM). Drops contained 3 ml of protein and 2 ml of reservoir solution
(30 mM MgOAc, 100 mM morpholino-ethane-sulphonic acid [MES,
pH 7.2], and 10% 2-methyl-2,4-pentanediol [MPD]).
The space group of proteasomal complex crystals belongs to P21,
with cell dimensions of a = 136.2 A˚, b = 300.7 A˚, c = 144.7 A˚, and b =
113.3º. Data to 2.8 A˚ were collected using synchrotron radiation with
l = 1.05 A˚ at the BW6-beamline at DESY, Hamburg, Germany. Crys-
tals were soaked in a cryoprotecting buffer (30% MPD, 20 mM
MgOAc, 100 mM MES, pH 6.9) and frozen in a stream of liquid nitro-
gen gas at 90K (Oxford Cryo Systems). X-ray intensities were evalu-
ated using the DENZO program and data reduction was performed
with SCALEPACK (Otwinowski et al., 2003; Otwinowski and Minor,
1997). Anisotropy of diffraction was corrected by an overall aniso-
tropic temperature factor, comparing observed and calculated
structure amplitudes using the program CNS (Bru¨nger et al., 1998).A total of 4,253,531 reflections yielded 249,075 unique reflections
(96.5% completeness). The corresponding Rmerge was 9.1% at
2.8 A˚ resolution (44.2% for the last resolution shell). Electron density
was improved by averaging and back-transforming reflections 10
times over the 2-fold noncrystallographic symmetry axis using the
program MAIN (Turk, 1992). Conventional crystallographic rigid
body, positional, and temperature factor refinements were carried
out with CNS using the yeast 20S proteasome structure as starting
model (Groll et al., 1997). For model building, the program MAIN
was used. The structure was refined to a crystallographic R-factor
of 23.1% (free R factor, 26.4%; Bru¨nger, 1993), with rmsds from
target values of 0.007 A˚ for bonds and 1.33º for angles (Engh and
Huber, 1991). Modeling experiments were performed using the coor-
dinates of yeast 20S proteasome (Groll et al., 1997) with the program
MAIN.
Proteasome Activity Assay with Fluorogenic Substrates
Assays were performed as previously described (Elliott et al., 2003)
with minor changes. Proteasome (100mg/ml) was incubated with var-
ious concentrations of bortezomib for 1 hr at 37ºC. An aliquot of 1 mg
was added to 100 ml of substrate buffer, containing 20 mM HEPES
(pH 8.2), 0.5 mM EDTA, 1% DMSO, and 180 mM BzValGlyArgAMC
(tryptic-like activity, b2), 100 mM SucLeuLeuValTyrAMC (chymotryp-
tic-like activity b5), or 180 mM ZLeuLeuGlu-bNA (caspase-like activity
b1). SDS was omitted from the substrate buffer. Fluorescence was
measured every minute for 35 min at 37ºC using a Fluostar Optima
96-well plate reader (BMG Labtechnologies) (lex/lem = 355/450 nm
for AMC and 320/405 nm for bNA), and the increase in fluorescence
per minute was used to calculate specific activities of each sample.
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